Doktorander/utbildningsplats

Sahlgrenska akademin utlyser doktorandplatser med placering vid institutionen för biomedicin, institutionen för medicin och institutionen för neurovetenskap och fysiologi.
Doktorandplatserna avser två års utbildningsbidrag och två års doktorandanställning, alternativt fyra års doktorandanställning, och beräknas leda fram till doktorsexamen.
För mer information och ansökningsblankett se: http://www.sahlgrenska.gu.se/doktorandportalen/doktor_fran_start_till_mal/soka_doktorandplats/

http://www.sahlgrenska.gu.se/doktorandportalen/Doktor_Fran_start_till_mal/doktorandplatser/


Development of new mucosal immunization approaches to induce protective immunity against primary and recurrent genital herpes

Application deadline: 2010-12-08

Description of the research project
Sexually transmitted infections constitute one of the major health problems in the world today.Genital herpes being the main cause of genital ulcers in humans with great socioeconomic burden, and its association with acquisition of HIV highlight the need to develop a vaccine to counter this sexually transmitted infection.Despite numerous efforts there is currently no vaccine for genital herpes for human use.This PhD proposal is planned as part of a research program with the goal of identification of potent vaccine adjuvant, antigen and vaccination approaches to generate protective immunity to primary and recurrent genital herpes simplex virus type 2 (HSV-2) infection.The main objective of this PhD project is to investigate the potential of lead HSV-2 vaccine antigens and adjuvants, which showed promise in our previous work to generate protective immunity to a mouse model of primary genital herpes as well as new candidates to be tested in mice, for induction of protective immunity to primary and recurrent genital herpes in a validated guinea pig model of primary and recurrent genital herpes.A series of readouts to examine systemic and mucosal immune responses as well as immunological assays will be established and employed.This project also plans to examine how peripheral blood immune cells obtained from genital herpes patients in comparison with healthy donors respond to the lead immunostimulatory adjuvants in vitro.